Arbutus Biopharma Analyst Ratings
H.C. Wainwright Maintains Arbutus Biopharma(ABUS.US) With Buy Rating, Maintains Target Price $5
Chardan Capital Maintains Arbutus Biopharma(ABUS.US) With Buy Rating, Maintains Target Price $4
Buy Rating Justified by Arbutus Biopharma's Strong Financials and Focused Clinical Strategy
JMP Securities Maintains Arbutus Biopharma(ABUS.US) With Buy Rating, Raises Target Price to $5
Arbutus Biopharma: Strategic Focus and Pipeline Promise Drive Buy Rating
Arbutus Biopharma Analyst Ratings
Arbutus Biopharma Analyst Ratings
Chardan Capital Maintains Buy on Arbutus Biopharma, Maintains $4 Price Target
Analysts Have Conflicting Sentiments on These Healthcare Companies: Ultragenyx Pharmaceutical (RARE), Hologic (HOLX) and Arbutus Biopharma (ABUS)
Arbutus Biopharma Analyst Ratings
Analysts Have Conflicting Sentiments on These Healthcare Companies: Arbutus Biopharma (ABUS), Neurocrine (NBIX) and Bausch Health Companies (BHC)
Analysts Are Bullish on Top Healthcare Stocks: Arbutus Biopharma (ABUS), Lemaitre Vascular (LMAT)
Arbutus Biopharma Analyst Ratings
Analysts Are Bullish on These Healthcare Stocks: Atossa Therapeutics (ATOS), Arbutus Biopharma (ABUS)
Analysts Offer Insights on Healthcare Companies: Arbutus Biopharma (ABUS), Twist Bioscience (TWST) and Catalent (CTLT)
Arbutus Biopharma Analyst Ratings
Buy Rating Affirmed for Arbutus Biopharma on Strong Clinical Outlook and Litigation Prospects
Chardan Capital Reaffirms Their Buy Rating on Arbutus Biopharma (ABUS)
Arbutus Biopharma: A Buy Rating on Strong Financial Footing and Promising Clinical Prospects